Read More

Cancer Player Aadi Bioscience Downgraded: Analyst Highlights ‘Worse Than Expected’ Response Rates

Friday, Aadi Bioscience Inc (NASDAQ: AADI) released results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial of nab-sirolimus in patients with 

AADI